10x Genomics (TXG) Payables (2018 - 2026)

10x Genomics has disclosed Payables across 9 years of filings, most recently posting $20.7 million for Q2 2026.

• In Q2 2026, Payables rose 29.84% year-over-year to $20.7 million; the TTM figure through Jun 2026 stood at $20.7 million (up 29.84% YoY), while the FY2025 annual figure was $12.7 million, down 1.36% from the prior year.
• Payables came in at $20.7 million for Q2 2026 at 10x Genomics, up from $17.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $29.3 million in Q1 2023 to a low of $10.1 million in Q1 2025.
• Average Payables over 5 years is $19.5 million, with a median of $19.6 million recorded in 2022.
• Year-over-year, Payables tumbled 50.2% in 2025 and jumped 73.07% in 2026.
• Over 5 years, Payables stood at $21.6 million in 2022, then fell by 27.14% to $15.7 million in 2023, then declined by 17.98% to $12.9 million in 2024, then retreated by 1.36% to $12.7 million in 2025, then surged by 62.52% to $20.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $20.7 million in Q2 2026, $17.4 million in Q1 2026, and $12.7 million in Q4 2025.